Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDA 002

Next Previous
Search
Drug Profile

PDA 002

Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscular

Latest Information Update: 16 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Celularity
  • Class Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Facioscapulohumeral muscular dystrophy
  • Discontinued Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders

Most Recent Events

  • 15 Oct 2024 Phase-I/II clinical trials in Facioscapulohumeral muscular dystrophy in USA (Parenteral), (Celularity pipeline, October 2024)
  • 20 Mar 2024 Celularity plans a phase I/II trial for Facioscapulohumeral Muscular Dystrophy in the second half of 2024
  • 20 Mar 2024 Celularity submits Orphan Drug designation application to US FDA for Facioscapulohumeral Muscular Dystrophy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top